-$0.84 EPS Expected for Coherus BioSciences (CHRS) This Quarter

Equities analysts predict that Coherus BioSciences (NASDAQ:CHRS) will announce earnings per share of ($0.84) for the current quarter, according to Zacks. Zero analysts have issued estimates for Coherus BioSciences’ earnings. Coherus BioSciences reported earnings of ($1.54) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 45.5%. The firm is expected to report its next earnings results on Monday, May 14th.

On average, analysts expect that Coherus BioSciences will report full-year earnings of ($3.00) per share for the current fiscal year, with EPS estimates ranging from ($3.29) to ($2.71). For the next fiscal year, analysts expect that the firm will report earnings of ($1.80) per share. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Coherus BioSciences.

How to Become a New Pot Stock Millionaire

Coherus BioSciences (NASDAQ:CHRS) last announced its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.02.

A number of brokerages have recently weighed in on CHRS. BidaskClub upgraded Coherus BioSciences from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. ValuEngine cut Coherus BioSciences from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Maxim Group restated a “buy” rating and issued a $15.00 price target (down previously from $20.00) on shares of Coherus BioSciences in a research report on Friday, March 9th. Citigroup raised their price target on Coherus BioSciences from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, March 9th. Finally, Zacks Investment Research upgraded Coherus BioSciences from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $29.33.

Shares of CHRS stock traded down $0.15 during mid-day trading on Wednesday, reaching $11.25. The stock had a trading volume of 263,993 shares, compared to its average volume of 788,021. Coherus BioSciences has a 12-month low of $8.05 and a 12-month high of $24.70. The stock has a market cap of $685.61, a P/E ratio of -2.52 and a beta of 3.39. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 3.33.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Teacher Retirement System of Texas acquired a new stake in shares of Coherus BioSciences during the fourth quarter valued at $101,000. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of Coherus BioSciences by 497.4% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,600 shares of the biotechnology company’s stock valued at $168,000 after acquiring an additional 10,491 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new stake in shares of Coherus BioSciences during the fourth quarter valued at $116,000. Bank of Montreal Can acquired a new stake in shares of Coherus BioSciences during the fourth quarter valued at $135,000. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Coherus BioSciences during the fourth quarter valued at $228,000. 82.29% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “-$0.84 EPS Expected for Coherus BioSciences (CHRS) This Quarter” was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3343774/0-84-eps-expected-for-coherus-biosciences-chrs-this-quarter.html.

About Coherus BioSciences

Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.

Get a free copy of the Zacks research report on Coherus BioSciences (CHRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Short Interest in Lilis Energy  Increases By 6.9%
Short Interest in Lilis Energy Increases By 6.9%
Globalstar  Short Interest Up 6.9% in April
Globalstar Short Interest Up 6.9% in April
Short Interest in Cheniere Energy Partners  Rises By 6.0%
Short Interest in Cheniere Energy Partners Rises By 6.0%
American Lorain Corp.  Sees Large Increase in Short Interest
American Lorain Corp. Sees Large Increase in Short Interest
Inphi  Posts Quarterly  Earnings Results, Hits Estimates
Inphi Posts Quarterly Earnings Results, Hits Estimates
Vicor  Releases  Earnings Results
Vicor Releases Earnings Results


© 2006-2018 Ticker Report. Google+.